Open-label Pilot Study of Abatacept for the Treatment of Vitiligo
Status:
Unknown status
Trial end date:
2018-05-01
Target enrollment:
Participant gender:
Summary
Vitiligo is a chronic autoimmune disease with evidence of CTLA-4 involvement. We are
performing a pilot study for the treatment of new onset or actively progressing vitiligo with
abatacept to determine if weekly self-injections of medication lead to clinical improvement
in vitiligo lesions.